Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 2 |
2023 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Front Endocrinol (Lausanne). 2022 Sep 16;13:957301. doi: 10.3389/fendo.2022.957301. eCollection 2022.
Front Endocrinol (Lausanne). 2022.
PMID: 36187106
Free PMC article.
AIM: This study aimed to assess whether clinical, biochemical, imaging and pathological characteristics can predict surgical remission and response to first-generation somatostatin receptor ligands (SRLs) and pasireotide-LAR in acromegaly. ...Fasting GH concentration <3 …
AIM: This study aimed to assess whether clinical, biochemical, imaging and pathological characteristics can predict surgical remissio …
Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly.
Rymuza J, Kober P, Rusetska N, Mossakowska BJ, Maksymowicz M, Nyc A, Baluszek S, Zieliński G, Kunicki J, Bujko M.
Rymuza J, et al.
Cells. 2022 Nov 30;11(23):3846. doi: 10.3390/cells11233846.
Cells. 2022.
PMID: 36497102
Free PMC article.
They differ in expression of numerous genes including those involved in growth hormone secretion and known prognostic genes. Transcriptomic subgroups can be distinguished by determining the expression of marker genes. ...Transcriptomic group 2 tumors are the most common (4 …
They differ in expression of numerous genes including those involved in growth hormone secretion and known prognostic genes. Transcri …
Item in Clipboard
MiR-320a Acts as a Tumor Suppressor in Somatotroph Pituitary Neuroendocrine Tumors by Targeting BCAT1.
Zhao S, Li B, Gao H, Zhang Y.
Zhao S, et al.
Neuroendocrinology. 2024;114(1):14-24. doi: 10.1159/000533549. Epub 2023 Aug 17.
Neuroendocrinology. 2024.
PMID: 37591221
Pan-cancer analyses demonstrated that high BCAT1 expression often indicates a poor prognosis. CONCLUSION: Our findings illustrate that miR-320a may function as a tumor suppressor and BCAT1 may promote tumor progression. miR-320a may inhibit the growth of somatotroph PitNET …
Pan-cancer analyses demonstrated that high BCAT1 expression often indicates a poor prognosis. CONCLUSION: Our findings illustrate tha …
Item in Clipboard
Cite
Cite